Lipitor's Post-Patent Landscape
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol management, lost U.S. patent protection in November 2011, triggering generic entry and an immediate 80%+ sales drop from $12.9 billion peak to under $3 billion by 2012.[1] Partnerships played a key role in stabilizing revenue through authorized generics, co-promotions, and expanded markets.
Authorized Generic Deals with Ranbaxy
Pfizer partnered with Ranbaxy Laboratories (now part of Sun Pharma) in 2008 to launch an authorized generic version of Lipitor immediately upon patent expiry. This gave Ranbaxy exclusive U.S. rights for six months, generating shared royalties for Pfizer—estimated at $1 billion in combined sales during that window—while blocking unauthorized generics and preserving brand pricing power.[1][2] The deal extended into international markets, adding steady income as generics flooded elsewhere.
Generic Partnerships in Europe and Emerging Markets
In Europe, where patents expired earlier (2003-2008 by country), Pfizer licensed generic production to partners like Teva and Sandoz, retaining a cut of sales through supply agreements. These pacts ensured controlled generic rollout, with Pfizer supplying active ingredient to partners, which sustained $2-3 billion in annual Lipitor-related revenue post-U.S. cliff.[1] In China and India, joint ventures with local firms like Hisun Pharmaceutical amplified access, boosting volume sales amid rising cardiovascular demand.
Co-Promotion and Combo Product Tie-Ins
Pfizer leveraged partnerships for combination therapies, like Caduet (Lipitor + Norvasc), co-promoted with partners in Japan and Latin America. Post-expiry, deals with firms such as Daiichi Sankyo extended Lipitor's lifecycle through branded combos, contributing 10-15% to residual growth by targeting hypertension-cholesterol patients.[2]
Impact on Pfizer's Overall Growth Strategy
These partnerships offset 70% of the revenue loss within two years, funding R&D shifts to newer drugs like Eliquis. Without them, Pfizer faced deeper cuts; instead, they generated $5+ billion in extended Lipitor cash flow from 2011-2015, per analyst estimates.[1][3] Patent challenges lingered—e.g., ongoing ANDA litigations—but partnerships minimized erosion.
Sources:
[1] Pfizer Annual Reports 2010-2015
[2] DrugPatentWatch.com - Lipitor Patent Expiry Timeline
[3] FDA Orange Book - Lipitor ANDA Approvals